Piramal Pharma Solutions unveils in-vitro biology capabilities at Ahmedabad Discovery Services Site

Published On 2023-10-18 06:01 GMT   |   Update On 2023-10-18 06:01 GMT

Mumbai: Piramal Pharma Limited’s Pharma Solutions (PPS) business, a Contract Development and Manufacturing Organization (CDMO), has formally announced the launch of a world-class high-throughput screening facility that augments the existing in-vitro biology capabilities at its drug discovery services site in Ahmedabad, India. This new expansion significantly adds primary and...

Login or Register to read the full article

Mumbai: Piramal Pharma Limited’s Pharma Solutions (PPS) business, a Contract Development and Manufacturing Organization (CDMO), has formally announced the launch of a world-class high-throughput screening facility that augments the existing in-vitro biology capabilities at its drug discovery services site in Ahmedabad, India. This new expansion significantly adds primary and secondary screening capabilities of compounds prepared at the Ahmedabad site. 

"With this expansion, Piramal Pharma Solutions is uniquely positioned to provide clients with an integrated set of discovery capabilities and leverage a wide range of in-vitro screening technology tools to support its broad portfolio of research services. The goal is to generate data that provides a superior data package for clients and enhance the company’s value as an outsourcing partner. The benefits of this new investment will be seen in an improved experience for PPS discovery services customers. The integration of chemistry and biology services under one roof promises to add high efficiency to the discovery process. To enable this expansion, PPS is committed to bringing in experienced personnel with a demonstrated track record in biology services, complementing the existing technical and operational expertise," the Company stated.

Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions said, “Through these enhanced in-vitro biology services, our drug discovery team will be able to provide clients with decision-driving information earlier and will be an even more effective partner in the drug discovery process.”

The new high-throughput screening format enables PPS to evaluate and screen large collections using various assay platform technologies including, but not limited to, TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) / HTRF (Homogeneous Time-Resolved Fluorescence), Fluorescence Polarization (FP), absorbance, Luminescence/Electrochemiluminescence (ECL), AlphaScreen, LanthaScreen, flow cytometry and high-content imaging..

These platforms will be applicable to a variety of targets including but not limited to G-Protein-Coupled Receptors (GPCRs) and kinases.
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News